GlassScriptPhysician profile
Diane M Levin
NPI 1689906703
$2,208.74
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,023 · 2020: $186.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $422.34 | 2019-2020 | |
| Pfizer INC. | $360.02 | 2019 | |
| Abbvie INC. | $249.89 | 2019 | |
| Akcea Therapeutics, INC. | $144.75 | 2019 | |
| Genentech, INC. | $129.24 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $124.99 | 2019 | |
| Radius Health, INC. | $124.95 | 2019 | |
| Biogen, INC. | $123.41 | 2019 | |
| Novartis Pharmaceuticals Corporation | $119.22 | 2019 | |
| Celgene Corporation | $110.25 | 2019 | |
| Melinta Therapeutics, LLC | $107.38 | 2019 | |
| Alexion Pharmaceuticals, INC. | $102.38 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.75 | 2019 | |
| Shire North American Group INC | $20.17 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Levin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.